Guselkumab as a switching strategy after anti-TNF alpha, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

Artículo original

Año: 2022

Ruiz-Villaverde, R; Rodriguez-Fernandez-Freire, L; Armario-Hita, JC; Perez-Gil, A; Chinchay, FV; Galan-Gutierrez, M

Título: DERMATOLOGIC THERAPY

• Q2